Biocartis Group NV
XBRU:BCART

Watchlist Manager
Biocartis Group NV Logo
Biocartis Group NV
XBRU:BCART
Watchlist
Price: 0.29 EUR Market Closed
Market Cap: 27.2m EUR
Have any thoughts about
Biocartis Group NV?
Write Note

Biocartis Group NV
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biocartis Group NV
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Biocartis Group NV
XBRU:BCART
Total Liabilities & Equity
€114.3m
CAGR 3-Years
-21%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Nyxoah SA
XBRU:NYXH
Total Liabilities & Equity
€124.2m
CAGR 3-Years
3%
CAGR 5-Years
47%
CAGR 10-Years
N/A
Ion Beam Applications SA
XBRU:IBAB
Total Liabilities & Equity
€597.5m
CAGR 3-Years
5%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Sequana Medical NV
XBRU:SEQUA
Total Liabilities & Equity
€10.8m
CAGR 3-Years
-25%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
No Stocks Found

Biocartis Group NV
Glance View

Market Cap
27m EUR
Industry
Health Care

Biocartis Group NV which engages in the development of oncology molecular diagnostic solutions. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 619 full-time employees. The company went IPO on 2015-04-27. The group has the Idylla system to deliver results within a period of between 35 to 150 minutes.

BCART Intrinsic Value
0.94 EUR
Undervaluation 69%
Intrinsic Value
Price

See Also

What is Biocartis Group NV's Total Liabilities & Equity?
Total Liabilities & Equity
114.3m EUR

Based on the financial report for Jun 30, 2023, Biocartis Group NV's Total Liabilities & Equity amounts to 114.3m EUR.

What is Biocartis Group NV's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
-7%

Over the last year, the Total Liabilities & Equity growth was 8%. The average annual Total Liabilities & Equity growth rates for Biocartis Group NV have been -21% over the past three years , -7% over the past five years .

Back to Top